Buy or sell Compass Therapeutics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Compass Therapeutics Stock

Compass Therapeutics is a biopharmaceutical company focused on drugging the immune system to treat human diseases.

About Compass Therapeutics Stock

We’re building Compass with a singular goal in mind: unlocking the complexity of the immune system. Our discovery and development teams work together to fully characterize and evaluate novel antibodies and rapidly generate therapeutic candidates. We are leveraging those insights to develop transformational therapies for cancer, inflammation and autoimmune diseases. We are a privately held company; our financing has been led by OrbiMed Advisors, F-Prime Capital, Cowen Healthcare Investments, Thiel Capital, Biomatics Capital, Borealis Ventures, Alexandria Real Estate Ventures and Biomed Realty Ventures.

Funding History

May 2015$575K
July 2015$16.0M
September 2016$50.0M
July 2018$49.0M

Management

CEO

Thomas Schuetz

Co-Founder, President/COO

Errik Anderson

Press

Compass Therapeutics Adds $49 Million to Series A

Wall Streets Journal - Jul, 12 2018

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Compass Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 80K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo